MX346115B - Metodo para mejorar la eliminación de virus en la purificacion proteica. - Google Patents

Metodo para mejorar la eliminación de virus en la purificacion proteica.

Info

Publication number
MX346115B
MX346115B MX2012001659A MX2012001659A MX346115B MX 346115 B MX346115 B MX 346115B MX 2012001659 A MX2012001659 A MX 2012001659A MX 2012001659 A MX2012001659 A MX 2012001659A MX 346115 B MX346115 B MX 346115B
Authority
MX
Mexico
Prior art keywords
viruses
elimination
improve
proteic purification
relates
Prior art date
Application number
MX2012001659A
Other languages
English (en)
Other versions
MX2012001659A (es
Inventor
Mehta Amit
Original Assignee
Genentech Inc *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42985499&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX346115(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc * filed Critical Genentech Inc *
Publication of MX2012001659A publication Critical patent/MX2012001659A/es
Publication of MX346115B publication Critical patent/MX346115B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Water Supply & Treatment (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere al campo de la purificación proteica. En particular, la invención se refiere a métodos para aumentar la capacidad de filtración de filtros de virus mediante el uso combinado de medios de eliminación de endotoxinas e intercambio catiónico en el proceso de prefiltración.
MX2012001659A 2009-08-06 2010-08-06 Metodo para mejorar la eliminación de virus en la purificacion proteica. MX346115B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23181109P 2009-08-06 2009-08-06
PCT/US2010/044760 WO2011031397A1 (en) 2009-08-06 2010-08-06 Method to improve virus removal in protein purification

Publications (2)

Publication Number Publication Date
MX2012001659A MX2012001659A (es) 2012-04-30
MX346115B true MX346115B (es) 2017-03-08

Family

ID=42985499

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012001659A MX346115B (es) 2009-08-06 2010-08-06 Metodo para mejorar la eliminación de virus en la purificacion proteica.

Country Status (25)

Country Link
US (5) US10662237B2 (es)
EP (3) EP2462158B1 (es)
JP (6) JP2013501075A (es)
KR (3) KR101844859B1 (es)
CN (2) CN106905413A (es)
AU (1) AU2010292897B2 (es)
BR (1) BR112012002574A2 (es)
CA (1) CA2770235C (es)
DK (1) DK2462158T3 (es)
ES (1) ES2662529T3 (es)
HR (1) HRP20180309T1 (es)
HU (1) HUE038451T2 (es)
IL (3) IL217740B (es)
LT (1) LT2462158T (es)
MX (1) MX346115B (es)
MY (1) MY188566A (es)
NO (1) NO2462158T3 (es)
NZ (1) NZ597809A (es)
PL (1) PL2462158T3 (es)
PT (1) PT2462158T (es)
RU (1) RU2573894C2 (es)
SG (1) SG178276A1 (es)
SI (1) SI2462158T1 (es)
WO (1) WO2011031397A1 (es)
ZA (1) ZA201200626B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8911964B2 (en) 2006-09-13 2014-12-16 Abbvie Inc. Fed-batch method of making human anti-TNF-alpha antibody
TWI456062B (zh) 2006-09-13 2014-10-11 Abbvie Inc 細胞培養改良
MX2011004201A (es) 2008-10-20 2011-05-24 Abbott Lab Desactivacion viral durante purificacion de anticuerpos.
AU2009347206C1 (en) 2008-10-20 2016-12-08 Abbvie Inc. Isolation and purification of antibodies using Protein A affinity chromatography
MX346115B (es) * 2009-08-06 2017-03-08 Genentech Inc * Metodo para mejorar la eliminación de virus en la purificacion proteica.
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
ES2685079T3 (es) 2011-03-25 2018-10-05 F. Hoffmann-La Roche Ag Procedimientos de purificación de proteínas novedosos
DE102011105525B4 (de) 2011-06-24 2015-03-26 Sartorius Stedim Biotech Gmbh Verfahren zur Abtrennung von Biopolymer-Aggregaten und Viren aus einem Fluid
US9096648B2 (en) 2011-08-19 2015-08-04 Emd Millipore Corporation Methods of reducing level of one or more impurities in a sample during protein purification
RU2648999C2 (ru) 2011-12-22 2018-03-29 Дженентек, Инк. Способы повышения эффективности этапов очистки белка, находящихся ниже по потоку, с использованием мембранной ионообменной хроматографии
ES2915378T3 (es) 2013-09-13 2022-06-22 Hoffmann La Roche Procedimientos para detectar y cuantificar una proteína de célula huésped en líneas celulares
EP4331605A3 (en) 2013-09-13 2024-05-22 F. Hoffmann-La Roche AG Methods and compositions comprising purified recombinant polypeptides
PT3209767T (pt) * 2014-10-21 2020-11-09 Gennova Biopharmaceuticals Ltd Um novo processo de purificação para isolamento e produção comercial de tnk-tpa recombinante (tenecteplase)
US20180072769A1 (en) * 2015-03-23 2018-03-15 Alexion Pharmaceuticals, Inc. Virus filtration
US11590452B2 (en) * 2017-06-12 2023-02-28 Asahi Kasei Medical Co., Ltd. Method for filtering protein-containing liquid
KR102753090B1 (ko) * 2017-12-21 2025-01-14 젠자임 코포레이션 단백질 a 크로마토그래피 동안 불순물의 향상된 제거를 위한 방법
TWI871300B (zh) * 2019-01-28 2025-02-01 美商安進公司 藉由將藥物物質和藥物產品過程整體化的生物製劑製造之連續製造過程

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
DE3850542T2 (de) 1987-09-23 1994-11-24 Bristol Myers Squibb Co Antikörper-Heterokonjugate zur Töting von HIV-infizierten Zellen.
ATE105585T1 (de) 1987-12-21 1994-05-15 Univ Toledo Transformation von keimenden pflanzensamen mit hilfe von agrobacterium.
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
JPH02198687A (ja) 1989-01-26 1990-08-07 Asahi Chem Ind Co Ltd 純水の製造方法
JPH038759A (ja) 1989-03-16 1991-01-16 Sumitomo Metal Ind Ltd 半導体磁器物質
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
EP0586505A1 (en) 1991-05-14 1994-03-16 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
EP0656064B1 (en) 1992-08-17 1997-03-05 Genentech, Inc. Bispecific immunoadhesins
WO1995001797A1 (en) * 1993-07-09 1995-01-19 Smithkline Beecham Corporation Protein purification
DK0668877T3 (da) * 1993-09-21 1999-09-13 Hemosol Inc Fortrængningschromatografisk fremgangsmåde og oprenset hæmoglobinprodukt
CA2106612C (en) 1993-09-21 2001-02-06 Diana Pliura Displacement chromatography process
JP3415222B2 (ja) 1993-10-20 2003-06-09 東洋濾紙株式会社 エンドトキシン吸着能を有するポリエーテルサルホン又はスルホン化ポリエーテルサルホン微孔膜
JP3453623B2 (ja) 1994-03-30 2003-10-06 サンスター株式会社 エンドトキシン吸着除去剤および除去方法
KR100378500B1 (ko) 1994-07-28 2003-05-22 밀리포어 코포레이션 복합다공성막및형성방법
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
FR2737730B1 (fr) * 1995-08-10 1997-09-05 Pasteur Merieux Serums Vacc Procede de purification de virus par chromatographie
JP3442788B2 (ja) * 1996-02-06 2003-09-02 ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング 精製核酸の製法及びその使用
TW505655B (en) 1997-10-14 2002-10-11 Tanox Inc Enhanced aggregate removal from bulk-biologicals using ion exchange chromatography
GB9907553D0 (en) * 1999-04-01 1999-05-26 Cantab Pharma Res Purification of biological preparations
JP3833533B2 (ja) 1999-07-30 2006-10-11 ジェネンテック・インコーポレーテッド 荷電濾過膜とその用途
ES2184594B1 (es) 2001-01-17 2004-01-01 Probitas Pharma Sa Procedimiento para la produccion de gammaglobulina g humana inactivada de virus.
US6806355B2 (en) 2001-08-14 2004-10-19 Statens Serum Institut Purification process for large scale production of Gc-globulin, the Gc-globulin produced hereby, a use of Gc.globulin and a Gc-globulin medicinal product
WO2003066669A2 (en) 2002-02-04 2003-08-14 Millipore Corporation Process for removing protein aggregates and virus from a protein solution
CA2478925C (en) 2002-04-26 2016-06-07 Robert Lee Fahrner Non-affinity purification of proteins
DK1545574T3 (da) 2002-09-13 2014-09-08 Biogen Idec Inc Fremgangsmåde til rensning af polypeptider ved simuleret moving-bed-chromatografi
US20040116676A1 (en) 2002-09-30 2004-06-17 Hotta Joann Methods for removal of contaminants from blood product solutions
EP1403274A1 (en) 2002-09-30 2004-03-31 Meristem Therapeutics Process for the purification of recombinant proteins from complex media and purified proteins obtained thereby
GB0304576D0 (en) 2003-02-28 2003-04-02 Lonza Biologics Plc Protein a chromatography
WO2004087761A1 (ja) 2003-03-31 2004-10-14 Kirin Beer Kabushiki Kaisha ヒトモノクローナル抗体およびヒトポリクローナル抗体の精製
JP4764818B2 (ja) 2003-04-11 2011-09-07 メディミューン，エルエルシー 組換えｉｌ−９抗体およびその使用
NZ547157A (en) * 2003-12-10 2009-07-31 Medarex Inc Interferon Alpha Antibodies and their uses
US8536315B2 (en) 2004-01-30 2013-09-17 Shire Pharmaceuticals Ireland Limited Production and purification of recombinant arylsulftase
JP2008500959A (ja) * 2004-01-30 2008-01-17 スオメン プナイネン リスティ ヴェリパルヴェル ウイルスについて安全な免疫グロブリンの製造方法
US7390403B2 (en) 2004-03-19 2008-06-24 Millipore Corporation Prefilter system for biological systems
EP1888208B1 (en) 2004-10-21 2012-11-14 Statens Serum Institut A method comprising nanofiltration to obtain an mbl product safe from infectious agents
CA2600601A1 (en) 2005-03-08 2006-09-14 Pharmacia & Upjohn Company Llc Anti-m-csf antibody compositions having reduced levels of endotoxin
WO2007108955A1 (en) * 2006-03-20 2007-09-27 Medarex, Inc. Protein purification
EP1854810A1 (en) 2006-05-09 2007-11-14 PanGenetics B.V. Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
US20100234577A1 (en) * 2006-06-14 2010-09-16 Smithkline Beecham Corporation Methods for purifying antibodies using ceramic hydroxyapatite
EA017733B1 (ru) 2006-08-28 2013-02-28 Арес Трейдинг С.А. СПОСОБ ОЧИСТКИ Fc-СЛИТЫХ БЕЛКОВ
WO2008036899A2 (en) 2006-09-22 2008-03-27 Amgen Inc. Methods for removing viral contaminants during protein purification
BRPI0718118A2 (pt) 2006-10-27 2017-05-30 Lpath Inc composições e métodos para ligação de sphingosine-1-fosfato
WO2008073620A2 (en) 2006-11-02 2008-06-19 Neose Technologies, Inc. Manufacturing process for the production of polypeptides expressed in insect cell-lines
ES2538986T3 (es) 2006-11-08 2015-06-25 Wyeth Llc Medios diseñados racionalmente para un cultivo celular
TWI601823B (zh) 2007-04-26 2017-10-11 中外製藥股份有限公司 Cell culture methods using media containing high concentrations of amino acids
BRPI0820604A2 (pt) 2007-12-21 2017-05-09 Genentech Inc método de purificação de um anticorpo cd20, cristal de um anticorpo cd20, composição e método destinado ao tratamento de uma condição ou doença associada ao cd20
EP2281000A2 (en) 2008-05-15 2011-02-09 Novo Nordisk A/S Antibody purification process
WO2010109920A1 (ja) * 2009-03-27 2010-09-30 旭化成メディカル株式会社 高濃度モノクローナル抗体溶液中のウイルス除去方法
MX2011012576A (es) 2009-05-27 2012-05-08 Baxter Int Metodo para producir una preparacion altamente concentrada de inmunoglobulina de uso subcutaneo.
MX346115B (es) 2009-08-06 2017-03-08 Genentech Inc * Metodo para mejorar la eliminación de virus en la purificacion proteica.
JP5787891B2 (ja) 2009-09-01 2015-09-30 ジェネンテック， インコーポレイテッド 改変されたプロテインａ溶離による向上したタンパク質精製

Also Published As

Publication number Publication date
PT2462158T (pt) 2018-02-23
CA2770235C (en) 2021-06-29
AU2010292897A1 (en) 2012-02-16
JP2023029853A (ja) 2023-03-07
HRP20180309T1 (hr) 2018-03-23
CN102712691A (zh) 2012-10-03
KR20190018041A (ko) 2019-02-20
EP3309168A1 (en) 2018-04-18
IL273486A (en) 2020-05-31
JP2013501075A (ja) 2013-01-10
WO2011031397A1 (en) 2011-03-17
LT2462158T (lt) 2018-03-26
KR101844859B1 (ko) 2018-05-18
EP4559926A2 (en) 2025-05-28
KR20180035936A (ko) 2018-04-06
JP2025003999A (ja) 2025-01-14
US20110034674A1 (en) 2011-02-10
SG178276A1 (en) 2012-03-29
SI2462158T1 (en) 2018-04-30
US20240083980A1 (en) 2024-03-14
PL2462158T3 (pl) 2018-05-30
EP2462158A1 (en) 2012-06-13
BR112012002574A2 (pt) 2020-11-03
JP2020023491A (ja) 2020-02-13
DK2462158T3 (en) 2018-03-05
ES2662529T3 (es) 2018-04-06
US11225513B2 (en) 2022-01-18
EP4559926A3 (en) 2025-08-06
IL273486B (en) 2022-04-01
RU2012108318A (ru) 2013-09-20
AU2010292897B2 (en) 2016-01-07
MY188566A (en) 2021-12-22
JP2016106096A (ja) 2016-06-16
NZ597809A (en) 2014-05-30
IL217740B (en) 2020-04-30
JP2017206529A (ja) 2017-11-24
CA2770235A1 (en) 2011-03-17
CN106905413A (zh) 2017-06-30
EP2462158B1 (en) 2018-01-10
US20200347118A1 (en) 2020-11-05
US10662237B2 (en) 2020-05-26
US20250282850A1 (en) 2025-09-11
US20220306726A1 (en) 2022-09-29
MX2012001659A (es) 2012-04-30
HUE038451T2 (hu) 2018-10-29
RU2573894C2 (ru) 2016-01-27
IL287431A (en) 2021-12-01
ZA201200626B (en) 2013-06-26
KR20130051431A (ko) 2013-05-20
NO2462158T3 (es) 2018-06-09
IL217740A0 (en) 2012-03-29

Similar Documents

Publication Publication Date Title
MX346115B (es) Metodo para mejorar la eliminación de virus en la purificacion proteica.
EA201990887A1 (ru) Вирусная фильтрация сред клеточных культур
MX2020004603A (es) Metodos de purificacion de arn mensajero.
AR091538A1 (es) Purificacion de particulas tipo virus
MX2013010737A (es) Novedosos metodos de purificacion de proteinas.
MX2021009891A (es) Metodos para purificar polisacaridos bacterianos.
MX349601B (es) Remocion de virus contaminantes de preparaciones de aav.
EA201070987A1 (ru) Очищенные гибридные белки иммуноглобулина и способы их очищения
MX392274B (es) Cartuchos utiles en limpieza de soluciones de dialisis.
EA201391166A1 (ru) Способ и система обработки воды, используемой для промышленных целей
EP2691170A4 (en) BIN-FREE ZEOLITIC ADSORPTION AGENTS, METHOD FOR PRODUCING BINDER-FREE ZEOLITIC ADSORPTION AGENTS, AND ADSORPTIVE SEPARATION PROCESSES USING BINDING-FREE ZEOLITE ADSORPTION AGENTS
EA201270557A1 (ru) Способ очистки аденовируса из культур с высокой плотностью клеток
EA201300604A1 (ru) Соединения, предназначенные для лечения респираторно-синцитиальных вирусных инфекций
PE20141386A1 (es) Sistemas de purificacion y mejoramiento del agua
WO2013028334A3 (en) Use of small molecules in methods for purification of biomolecules
BR112013025614A2 (pt) "métodos para purificação de hidrofobina ii e uso de um álcool para purificar a referida hidrofobina".
DE112012000715A5 (de) Verfahren zur Reinigung von Gasen oder Flüssigkeiten, Adsorbens dafür, Filter, sowie Verwendung des Adsorptionsmittels
BR112013029147A2 (pt) meio de filtração de líquidos, sistema de filtração para filtrar as partículas dos líquidos e processo para a produção de um meio de filtração de líquidos
MX2018003080A (es) Cartuchos utiles en soluciones de dialisis de limpieza.
MY188877A (en) Method to improve virus removal in protein purification
PL2286887T3 (pl) Usuwanie endotoksyn ze środków kontrastowych
NZ708503A (en) Purification of x-ray contrast agents
WO2013190453A3 (en) Compositions for separation methods
WO2012082723A3 (en) Purification of immunogens using a non-polysaccharide matrix
FI20115265A0 (fi) Menetelmä ja suodatusjärjestely kaasuprosessissa

Legal Events

Date Code Title Description
FG Grant or registration